查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1609186

非侵入性液態切片市場：按類型、技術和最終用戶分類 - 全球預測 2025-2030

Non-Invasive Liquid Biopsy Market by Type (Assay Kits, Instruments, Services), Technology (Next Generation Sequencing (NGS), RT-PCR and dPCR), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，非侵入性液態切片市場價值為10.1億美元，預計2024年將達到11.9億美元，複合年成長率為18.10%，到2030年將達到32.5億美元。

非侵入性液態切片是一種用於檢測和監測癌症的尖端診斷方法，為傳統組織切片檢查提供了一種侵入性較小的替代方案。分析血液等體液中的循環性腫瘤細胞(CTC)、無細胞 DNA (cfDNA) 和 RNA，無需手術介入即可提供腫瘤動態的重要見解。對非侵入性液態切片的需求解決了組織切片檢查的局限性，例如採樣偏差和潛在的手術併發症，並且能夠促進癌症的早期檢測、監測治療效果和檢測復發性疾病。其應用涵蓋腫瘤學、個人化醫療和產前檢測，並用於醫院、診斷中心和學術機構。關鍵的成長要素包括基因組學和蛋白​​質組學的進步、癌症發生率的增加以及對微創診斷技術的需求增加。此外，研究和開發活動的迅速增加以及對癌症早期檢測的認知不斷提高正在激活市場。

主要市場統計
基準年[2023] 10.1億美元
預測年份 [2024] 11.9億美元
預測年份 [2030] 32.5億美元
複合年成長率（%） 18.10%

然而，挑戰包括高成本、監管複雜性以及測試敏感性和特異性問題。為了克服這些限制，必須制定標準化通訊協定並透過強力的檢驗研究證明臨床效用。市場相關人員應專注於創新分子診斷技術，提高測試準確性，並整合人工智慧和機器學習進行資料分析。生物製藥公司、研究機構和醫療保健提供者之間的夥伴關係和合作對於利用專業知識和擴大市場範圍至關重要。還存在將應用擴展到其他疾病類型、改進多參數檢測以及開發即時液態切片設備的機會。投資擴大我們對腫瘤生物學和抗藥性機制的理解可以進一步提升液態切片作為癌症管理的變革工具的地位。市場充滿活力且競爭激烈，需要持續創新和策略聯盟來駕馭不斷變化的格局並最大限度地實現業務成長。

市場動態：快速發展的非侵入性液態切片市場的關鍵市場洞察

非侵入性液態切片市場正在因供需的動態相互作用而發生轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症發生率和盛行率上升
    • 對非侵入性診斷方法的日益偏好
  • 市場限制因素
    • 先進的非侵入性液態切片高成本
  • 市場機會
    • 人工智慧與非侵入性液態切片相結合
    • 增加對先進醫療基礎設施的投資
  • 市場挑戰
    • 不同技術和腫瘤類型缺乏標準化

波特五力：駕馭非侵入性液態切片市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對非侵入性液態切片市場的外部影響

外部宏觀環境因素在塑造非侵入性液態切片市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解非侵入性液態切片市場的競爭格局

非侵入性液態切片市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV定位矩陣非侵入性液態切片市場供應商績效評估

FPNV 定位矩陣是評估非侵入性液態切片市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了非侵入性液態切片市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對非侵入性液態切片市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率和盛行率上升
      • 對非侵入性診斷方法的興趣日益濃厚
    • 抑制因素
      • 先進的非侵入性液態切片高成本
    • 機會
      • 人工智慧與非侵入性液態切片相結合
      • 增加對先進醫療基礎設施的投資
    • 任務
      • 不同技術和腫瘤類型缺乏標準化
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章無創液態切片市場：按類型

  • 檢測試劑套件
  • 裝置
  • 服務

第7章無創液態切片市場：依技術分類

  • 次世代定序（NGS）
  • RT-PCR 和 dPCR

第8章無創液態切片市場：按最終用戶分類

  • 學術研究中心
  • 臨床診斷實驗室
  • 醫院

第9章美洲無創液態切片市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太無創液態切片市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲無創液態切片市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Angle PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocept, Inc.
  • DiaCarta, Inc.
  • Epic Sciences Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group Ltd.
  • Lucence Diagnostics Pte. Ltd.
  • LungLife AI, Inc.
  • Mdxhealth BV
  • MedGenome Labs Ltd.
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Nonacus Limited
  • Norgen Biotek Corporation
  • Oasis Diagnostics Corporation
  • OraSure Technologies, Inc
  • QIAGEN GmbH
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corp.
Product Code: MRR-5C6F41F5B02E

The Non-Invasive Liquid Biopsy Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.19 billion in 2024, and is projected to grow at a CAGR of 18.10%, to USD 3.25 billion by 2030.

Non-invasive liquid biopsy is a cutting-edge diagnostic method used for cancer detection and monitoring, providing a less invasive alternative to traditional tissue biopsies. It involves analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), or RNA in bodily fluids like blood, offering critical insights into tumor dynamics without the need for surgical procedures. The necessity of non-invasive liquid biopsies lies in their ability to facilitate early cancer detection, monitor treatment efficacy, and detect recurrent disease, addressing the limitations of tissue biopsies, such as sampling bias and potential surgical complications. Their applications span across oncology, personalized medicine, and prenatal testing, with usage in hospitals, diagnostic centers, and academic institutions. Key growth factors include advancements in genomics and proteomics, growing cancer prevalence, and increasing demand for minimally invasive diagnostic techniques. Additionally, the surge in research and development activities and growing awareness about early cancer detection are fueling the market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.19 billion
Forecast Year [2030] USD 3.25 billion
CAGR (%) 18.10%

However, challenges include high costs, regulatory complexities, and issues related to test sensitivity and specificity. Overcoming these limits will entail developing standardized protocols and demonstrating clinical utility through robust validation studies. Market players should focus on innovation in molecular diagnostic technologies, enhancing test accuracy, and integrating AI and machine learning for data analysis. Partnerships and collaborations between biopharma companies, research institutes, and healthcare providers are vital to leverage expertise and expand market reach. Opportunities exist in expanding applications to other disease types, improving multi-analyte detection, and developing point-of-care liquid biopsy devices. Investing in expanding the understanding of tumor biology and resistance mechanisms could further elevate liquid biopsy as a transformative tool in cancer management. The market is dynamic and competitive, requiring continuous innovation and strategic collaborations to navigate the evolving landscape and maximize business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-Invasive Liquid Biopsy Market

The Non-Invasive Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence and prevalence of cancer
    • Increasing preference for noninvasive diagnostic procedures
  • Market Restraints
    • High cost associated with advanced non-invasive liquid biopsy
  • Market Opportunities
    • Integration of artificial intelligence with non-invasive liquid biopsy
    • Increasing investment for advanced healthcare infrastructure
  • Market Challenges
    • Lack of standardization across different techniques and tumor types

Porter's Five Forces: A Strategic Tool for Navigating the Non-Invasive Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-Invasive Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-Invasive Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-Invasive Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-Invasive Liquid Biopsy Market

A detailed market share analysis in the Non-Invasive Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-Invasive Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-Invasive Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-Invasive Liquid Biopsy Market

A strategic analysis of the Non-Invasive Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-Invasive Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Angle PLC, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocept, Inc., DiaCarta, Inc., Epic Sciences Inc., F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Lucence Diagnostics Pte. Ltd., LungLife AI, Inc., Mdxhealth BV, MedGenome Labs Ltd., Menarini Silicon Biosystems SpA, Merck KGaA, Nonacus Limited, Norgen Biotek Corporation, Oasis Diagnostics Corporation, OraSure Technologies, Inc, QIAGEN GmbH, Thermo Fisher Scientific Inc., and Zymo Research Corp..

Market Segmentation & Coverage

This research report categorizes the Non-Invasive Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Assay Kits, Instruments, and Services.
  • Based on Technology, market is studied across Next Generation Sequencing (NGS) and RT-PCR and dPCR.
  • Based on End-user, market is studied across Academic & Research Centers, Clinical Diagnostic Laboratories, and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence and prevalence of cancer
      • 5.1.1.2. Increasing preference for noninvasive diagnostic procedures
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced non-invasive liquid biopsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence with non-invasive liquid biopsy
      • 5.1.3.2. Increasing investment for advanced healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardization across different techniques and tumor types
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Non-Invasive Liquid Biopsy Market, by Type

  • 6.1. Introduction
  • 6.2. Assay Kits
  • 6.3. Instruments
  • 6.4. Services

7. Non-Invasive Liquid Biopsy Market, by Technology

  • 7.1. Introduction
  • 7.2. Next Generation Sequencing (NGS)
  • 7.3. RT-PCR and dPCR

8. Non-Invasive Liquid Biopsy Market, by End-user

  • 8.1. Introduction
  • 8.2. Academic & Research Centers
  • 8.3. Clinical Diagnostic Laboratories
  • 8.4. Hospital

9. Americas Non-Invasive Liquid Biopsy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Non-Invasive Liquid Biopsy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Non-Invasive Liquid Biopsy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Angle PLC
  • 2. Bio-Rad Laboratories, Inc.
  • 3. Bio-Techne Corporation
  • 4. Biocept, Inc.
  • 5. DiaCarta, Inc.
  • 6. Epic Sciences Inc.
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Guardant Health, Inc.
  • 9. Illumina, Inc.
  • 10. Integrated DNA Technologies, Inc.
  • 11. Laboratory Corporation of America Holdings
  • 12. Lonza Group Ltd.
  • 13. Lucence Diagnostics Pte. Ltd.
  • 14. LungLife AI, Inc.
  • 15. Mdxhealth BV
  • 16. MedGenome Labs Ltd.
  • 17. Menarini Silicon Biosystems SpA
  • 18. Merck KGaA
  • 19. Nonacus Limited
  • 20. Norgen Biotek Corporation
  • 21. Oasis Diagnostics Corporation
  • 22. OraSure Technologies, Inc
  • 23. QIAGEN GmbH
  • 24. Thermo Fisher Scientific Inc.
  • 25. Zymo Research Corp.

LIST OF FIGURES

  • FIGURE 1. NON-INVASIVE LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NON-INVASIVE LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NON-INVASIVE LIQUID BIOPSY MARKET DYNAMICS
  • TABLE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RT-PCR AND DPCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023